SUDEEPPHRM
SUDEEP PHARMA LIMITED
SUDEEP PHARMA LIMITED (SUDEEPPHRM) Stock Analysis & Case Study
Is SUDEEPPHRM a good buy? The data-driven verdict.
SUDEEP PHARMA LIMITED (SUDEEPPHRM) trades at ₹974,on the numbers it mixed signals, a Downstox Snapshot Score of 52/100.
On the numbers, SUDEEP PHARMA LIMITED (SUDEEPPHRM) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 60.4× earnings, ROE of 25.2%. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
SUDEEPPHRM fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How SUDEEPPHRM ranks against the 2,373 companies in our screener
- SUDEEPPHRM's market cap of 10,815 Cr ranks in the 76th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUDEEPPHRM's book value of ₹78 ranks in the 45th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUDEEPPHRM's promoter holding of 76.2% ranks in the top 3% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUDEEPPHRM's 3-year profit (PAT) growth of 40.0% ranks in the 78th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUDEEPPHRM's 3-year revenue growth of 14.0% ranks in the 60th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUDEEPPHRM's debt-to-equity ratio of 0.17x is lower than 66% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is SUDEEPPHRM overvalued? SUDEEPPHRM P/E vs peers
SUDEEPPHRM trades at 60.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
The bull case for SUDEEPPHRM
- SUDEEPPHRM's return on equity of 25.2% ranks in the 90th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- SUDEEPPHRM's return on capital employed of 28.2% ranks in the 91st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
The bear case & risks
- SUDEEPPHRM's P/E of 59.2x is lower than 21% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 12.5× price-to-book means most of the value is intangible/expectations, not assets on the books.
SUDEEPPHRM Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. SUDEEPPHRM scores 6/8, mixed financial health.
SUDEEPPHRM MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy SUDEEPPHRM with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 31.68% | 3.2× |
| Groww | 31.71% | 3.2× |
| Dhan | 31.68% | 3.2× |
| Kotak Neo | 40.00% | 2.5× |
| Paytm Money | 31.71% | 3.2× |
| PocketfulCHEAPEST | 30.96% | 3.2× |
| Fyers | 31.25% | 3.2× |
| Anand Rathi | 31.68% | 3.2× |
| Share India | 31.06% | 3.2× |
Compare every broker on the SUDEEPPHRM MTF page.
About SUDEEP PHARMA LIMITED: sector, index & market-cap context
SUDEEP PHARMA LIMITED (SUDEEPPHRM) is a small-cap NSE-listed company, with a market capitalisation of ₹11,033 Cr. See more stocks on our screener.
How the SUDEEPPHRM Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of SUDEEP PHARMA LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
SUDEEPPHRM analysis, FAQs
Is SUDEEP PHARMA LIMITED (SUDEEPPHRM) a good buy?
On the numbers, SUDEEP PHARMA LIMITED (SUDEEPPHRM) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 60.4× earnings, ROE of 25.2%. This is a data snapshot for research, not investment advice.
Is SUDEEPPHRM overvalued or undervalued?
SUDEEPPHRM trades at 60.4× earnings, expensive versus the ~22× long-run Nifty average.
What is the bull case for SUDEEPPHRM?
SUDEEPPHRM's return on equity of 25.2% ranks in the 90th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. SUDEEPPHRM's return on capital employed of 28.2% ranks in the 91st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in SUDEEPPHRM?
SUDEEPPHRM's P/E of 59.2x is lower than 21% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 12.5× price-to-book means most of the value is intangible/expectations, not assets on the books.